All In Biotech

Drug Trial Radar · NCT06895356

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

A Phase 1, Two Part, Randomized, Single and Multiple Dose Crossover Study to Assess the Relative Bioavailability Between Tavapadon Clinical and Commercial Tablets

Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

83

Actual

Start

Mar 26, 2025

Primary completion

Jun 16, 2025

Study completion Jun 16, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the relative bioavailability of two different Oral formulations of tavapadon in healthy adult participants.

Conditions

  • Healthy Volunteer

Interventions

  • TavapadonDrug

    Oral: Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 53 days
  2. Maximum Observed Plasma Concentration (Cmax) of TavapadonTime frame: Up to approximately 22 days
  3. Time to Cmax (Tmax) of TavapadonTime frame: Up to approximately 22 days
  4. Apparent Terminal Phase Elimination Rate Constant (β) of TavapadonTime frame: Up to approximately 22 days
  5. Terminal Phase Elimination Half-life (t1/2) of TavapadonTime frame: Up to approximately 22 days
  6. Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of TavapadonTime frame: Up to approximately 22 days
  7. Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of TavapadonTime frame: Up to approximately 22 days
  8. Trough Concentration (Ctrough) of TavapadonTime frame: Up to approximately 22 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Acpru /Id# 275870

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.